Comments TOKYO, Sept. 26, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it received approval from the Ministry of Health, Labour and Welfare inJapan for LIXIANA® (JAN: Edoxaban Tosilate ... AndhraNews.net, 23 hours ago
DAIICHI SANKYO : and Daiichi Sankyo Espha Submit Supplemental New Drug Application in Japan for Cravit® Tablets, Granules and Levofloxacin Tablets, Granules DSEP - 4 Traders, 10 hours ago
Daiichi Sankyo adquiere Ambit Biosciences - PR Newswire, 1 day ago
More from: Reuters UK, Stock Nod...and 91 other sources
(MENAFN) Daiichi Sankyo Co., Japan's pharmaceutical firm, said it has reached an agreement to acquire US company Ambit Biosciences for USD410 million, QNA reported. The Japanese company said the move aims to establish its presence in the oncology ...MENAFN, 2 days ago Japan's Sankyo Acquires US Pharmaceutical Firm for $410 Million Qatar News Agency, 1 day ago
AMBIT BIOSCIENCES : Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Daiichi Sankyo Company, Ltd.
NEW YORK, Sept. 29, 2014 /PRNewswire/ -- Bernstein Liebhard LLP is investigating whether the Board of Directors of Ambit Biosciences ("Ambit Biosciences" or the "Company") (NASDAQ: AMBI) breached its fiduciary duty to its shareholders in agreeing to ...4 Traders, 1 day ago Glancy Binkow & Goldberg LLP is Investigating Ambit Biosciences Corporation Board of Directors Industrial Info Financials, 1 day ago SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Ambit Biosciences Corporation in Connection with the Sale of the Company -AMBI Review Seeker, 10 hours ago Harwood Feffer LLP Announces Investigation Of Ambit Biosciences Corporation TheStreet.com, 1 day ago
Japan's Daiichi Sankyo has agreed to acquire San Diego cancer drug developer Ambit Biosciences (NASDAQ: AMBI) for $315 million in cash, with additional milestone payments that could bring the total to $410 million. The transaction comes just over a ...Xconomy, 1 day ago DAIICHI SANKYO : to buy U.S. bio-firm to boost cancer drug development 4 Traders, 2 days ago Daiichi Sankyo bags leukemia drug in $410M Ambit buyout FierceBiotech, 2 days ago Daiichi Sankyo to buy U.S. bio-firm to boost cancer drug development Pharmacy Choice, 2 days ago
Ambit Biosciences Corp (NASDAQ: AMBI) +85% - The company formally announced that Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share. Einstein Noah Restaurant Group, Inc. (NASDAQ: BAGL) +50% - The ...Benzinga.com, 1 day ago
AMBIT SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Buyout by Daiichi Sankyo
Company Website: http://www.powerstaylor.com DALLAS -- (Business Wire) Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating ...Stockwatch, 1 day ago
EQUITY ALERT: Rosen Law Firm Announces Investigation of Ambit Biosciences Corporation Concerning its Proposed Sale to Daiichi Sankyo Company, Ltd.
Company Website: http://rosenlegal.com/cases-381.html NEW YORK -- (Business Wire) The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of Ambit Biosciences Corporation (NASDAQ:AMBI) for possible ...Stockwatch, 15 hours ago Ambit Biosciences : EQUITY ALERT: Rosen Law Firm Announces Investigation of Ambit Biosciences Corporation Concerning its Proposed Sale to Daiichi Sankyo Company, Ltd. 4 Traders, 15 hours ago
-- Le composé chimique phare, le Quizartinib, va renforcer le portefeuille de traitements cancérologiques de Daiichi Sankyo TOKYO et SAN DIEGO , 29 septembre 2014 /PRNewswire/ -- Daiichi Sankyo Company, Ltd. (ci-après désignée Daiichi ...PR Newswire, 1 day ago
NEW YORK (TheStreet) -- Shares of Ambit Biosciences (AMBI) Daiichi Sankyo cited Ambit's drug candidate quizartinib, which is in late-stage trials for the treatment of acute myeloid leukemia, as the primary reason for the purchase. The offer of $15 ...TheStreet.com, 1 day ago
Acute Coronary Syndrome - Current and Future Players: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharma, Merck, Pfizer & Sanofi
Research and Markets (http://www.researchandmarkets.com/research/lx7n7r/pharmapoint) has announced the addition of the "PharmaPoint: Acute Coronary Syndrome - Current and Future Players" report to their offering. The report is a vital source of ...Individual.com, 6 days ago Jay Feingold appointed CMO at ADC Therapeutics amid large-scale hiring drive Pharma Letter, 1 day ago Anaplastic Thyroid Cancer Therapeutics Pipeline Review 2014 - 7 Companies & 11 Drug profiles Individual.com, 1 week ago Research and Markets: Acute Coronary Syndrome - Current and Future Players: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharma, Merck, Pfizer & Sanofi Morningstar.com, 6 days ago
on your WebpageAdd Widget >Get your members hooked!